Free shipping on all orders over $ 500

ROC-325

Cat. No. M6260

All AbMole products are for research use only, cannot be used for human consumption.

ROC-325 Structure
Size Price Availability Quantity
1mg USD 30 In stock
5mg USD 60 In stock
10mg USD 95 In stock
25mg USD 200 In stock
50mg USD 320 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

In vitro: Treatment with ROC-325 triggers all of the hallmark features of autophagy inhibition including the accumulation of autophagosomes with undegraded cargo, an increase in lysosomal membrane permeability, deacidification of lysosomes, and elevated LC3B, p62, and cathepsin D expression. In vitro treatment of a panel of human AML cell lines and normal human bone marrow progenitors demonstrate that ROC-325 diminishes AML cell viability (IC50 range 0.7-2.2 µM), antagonizes clonogenic survival, and induces apoptosis in a manner that is therapeutically selective.

In vivo: ROC-325 is well tolerated and no notable toxicities are observed other than a modest, non-significant reversible reduction in mean body weight. Oral administration of ROC-325 to mice bearing RCC xenografts is well tolerated and yields dose-dependent inhibition of tumor growth that is significantly more efficacious than a higher dose of HCQ.

Protocol (for reference only)
Cell Experiment
Cell lines RCC cells
Preparation method RCC cells were treated with ROC-325 for 24 h and harvested for imaging. Briefly, sections were cut in an LKB Ultracut microtome (Leica), stained with uranyl acetate and lead citrate, and examined in a JEM 1230 transmission electron microscope.
Concentrations 1 μM
Incubation time 24 h
Animal Experiment
Animal models Mice
Formulation water
Dosages 25, 40, and 50 mg/kg
Administration p.o.
Chemical Information
Molecular Weight 503.06
Formula C28H27ClN4OS
CAS Number 1859141-26-6
Solubility (25°C) 4 mg/mL in DMSO
Storage Powder          -20°C   3 years ;  4°C   2 years
In solvent       -80°C   6 months ;  -20°C   1 month
References

[1] Carew JS, et al. Autophagy. Drain the lysosome: Development of the novel orally available autophagy inhibitor ROC-325.

[2] Carew JS, et al. Clin Cancer Res. Disruption of Autophagic Degradation with ROC-325 Antagonizes Renal Cell Carcinoma Pathogenesis.

Related Autophagy Products
Tacrolimus (FK506)

Tacrolimus (FK506, FR900506, Fujimycin, Prograf) is a potent, clinically-useful immunosuppressant in the same molecular class as cyclosporin A and rapamycin. *The compound is unstable in solutions, freshly prepared is recommended

Metformin hydrochloride

Metformin HCl is a biguanide inhibitor that reduces blood glucose mainly by inhibiting hepatic glycogen production (hepatic gluconeogenesis), while Metformin is a CD47 inhibitor in vitro.

Ginkgolide K

Ginkgolide K induces protective autophagy through the AMPK/mTOR/ULK1 signaling pathway.

Ivermectin (MK-933)

Ivermectin (MK-933) is a positive allosteric modulator of the α7 neuronal nicotinic acetylcholine receptor and the purinergic P2X4 receptor. Importin α5 inhibitor ivermectin effectively abrogates STAT1-importin α5 interactions.

Bergapten

Bergapten is a psoralen that can be photoactivated and is capable of crossing-linking DNA, covalently modifying proteins and lipids, and consequently inhibiting cell replication.

  Catalog
Abmole Inhibitor Catalog




Keywords: ROC-325 supplier, Autophagy, inhibitors, activators

All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.



Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2026 AbMole BioScience. All Rights Reserved.